Jean-François Formela is a partner in the life sciences group and joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Annovation Biopharma (acquired by The Medicines Company), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), and SGX Pharmaceuticals (NASDAQ: SGXP acquired by Lilly).
He was also an investor in Achillion (NASDAQ: ACHN), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) and a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).
He serves on the boards of Ataxion, Egalet (NASDAQ: EGLT), F-star, Intellia Therapeutics, Navitor, RaNA Therapeutics which he also co-founded Spero Therapeutics and ZappRx.
Prior to joining Atlas, Jean-François worked at Schering-Plough in the U.S. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. He received his MD from Paris University School of Medicine, and his MBA from Columbia University.